01—Abstract
Summary
Summary of the 10-Q filed February 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Cardinal Health Inc. (CAH) reported a strong second quarter for fiscal year 2024, with total revenue increasing by 12% year-over-year to $57.4 billiona.
This growth was primarily driven by increased branded and specialty pharmaceutical sales within its Pharmaceutical segment. The company also demonstrated significant improvements in profitability, with non-GAAP operating earnings up 20%b and non-GAAP diluted EPS rising 38% year-over-year. This enhanced performance is attributed to stronger contributions from both the Pharmaceutical and Medical segments.
Looking ahead, Cardinal Health announced a significant strategic move with the definitive agreement to acquire Specialty Networks for $1.2 billionc in cash. This acquisition is expected to bolster the company's offerings in key therapeutic areas by enhancing analytics capabilities and accelerating data and research opportunities with biopharma manufacturers. The company also maintains a healthy liquidity position, with cash and equivalents increasing to $4.6 billion, supported by robust operating cash flow, and continues its capital return strategy through share repurchases and dividends.
02—Key points
Key Highlights
- Revenue increased 12% to $57.4 billion for Q2 FY2024, driven by pharmaceutical sales growth.
- Non-GAAP operating earnings grew 20% to $562 million, and non-GAAP diluted EPS increased 38% to $1.82 year-over-year.
- Announced definitive agreement to acquire Specialty Networks for $1.2 billion to expand offerings in key therapeutic areas.
- Pharmaceutical segment profit increased 12%, benefiting from generics program performance and COVID-19 vaccine distribution.
- Medical segment profit saw a significant increase due to favorable comparisons to prior-year inflationary impacts and mitigation actions.
- Cash and equivalents increased to $4.6 billion at December 31, 2023.
- Completed $750 million in share repurchases and paid $255 million in dividends during the first six months of FY2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Cardinal Health Inc kept $0.01.
- Revenue$57.44B100.0%
- Cost of revenue−$55.59B96.8%
- Gross profit$1.85B3.2%
- Operating costs−$1.35B2.3%
- Operating income$505.0M0.9%
- Interest, other & tax−$137.0M0.2%
- Net income$368.0M0.6%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed February 1, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $57.44B$51.47B | +11.6% |
| Cost of Revenue | $55.59B$49.78B | +11.7% |
| Gross Profit | $1.85B$1.68B | +10.1% |
| SG&A Expenses | $1.27B$1.18B | +7.5% |
| Operating Income | $505.00M-$86.00M | +687.2% |
| Interest Expense | $3.00M$24.00M | −87.5% |
| Net Income | $368.00M-$77.00M | +577.9% |
| EPS (Basic) | $1.50$-0.30 | +600.0% |
| EPS (Diluted) | $1.50$-0.30 | +600.0% |
| Shares Outstanding (Basic) | 245.00M261.00M | −6.1% |
| Shares Outstanding (Diluted) | 246.00M261.00M | −5.7% |
05—Questions
Frequently Asked Questions
What were the main drivers of Cardinal Health's revenue growth in Q2 FY2024?
Cardinal Health's revenue increased by 12% to $57.4 billion, primarily driven by growth in branded and specialty pharmaceutical sales from existing customers within its Pharmaceutical segment. The Medical segment also contributed with sales growth in at-Home Solutions and products and distribution, including higher Cardinal Health brand volumes and price increases to offset inflation.
How did the company's profitability improve in Q2 FY2024?
Profitability improved significantly, with GAAP operating earnings turning positive at $482 million compared to a loss of $119 million in the prior year. Non-GAAP operating earnings increased by 20% to $562 million, and non-GAAP diluted EPS rose by 38% to $1.82. These improvements were supported by increased profit in both the Pharmaceutical and Medical segments, despite excluding large items like goodwill impairment charges.
What is the strategic significance of the announced acquisition of Specialty Networks?
The acquisition of Specialty Networks for $1.2 billion is a key strategic move designed to expand Cardinal Health's offerings in critical therapeutic areas. It aims to enhance downstream provider-focused analytics capabilities and service offerings, while also accelerating upstream data and research opportunities with biopharma manufacturers.
How is the company managing its liquidity and capital deployment?
Cardinal Health maintains a strong liquidity position, with cash and equivalents at $4.6 billion as of December 31, 2023. Net cash provided by operating activities was $1.7 billion for the first six months of FY2024. The company is actively returning capital to shareholders through share repurchases ($750 million in the period) and dividends ($255 million paid). The company also has significant unused credit facilities and a $3.5 billion share repurchase authorization remaining.
06—Continue